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A B S T R A C T
The –omics technologies are becoming increasingly important in health care and are expected to contribute to
personalized health care. In a typical experiment, cases and controls are compared as a two-class classiﬁcation
problem. This approach is often unsuitable, for example, because the classes are not well deﬁned due to
associated populations being biologically too heterogeneous. Recently, statistical health monitoring (SHM) was
introduced as a complementary approach to allow for predictions at the individual level. This approach could be
of use in all sorts of applications such as diagnosis of rare diseases, analysis of individual patterns in disease
manifestation, disease monitoring, or personalized therapy.
SHM uses the framework of statistical process monitoring (SPM) in a clinical setting. The method essentially
combines estimation of Mahalanobis distances (MD) with principal component analysis (PCA) to evaluate the
diﬀerence in the –omics data of an individual subject to a normal reference range (normal operating conditions).
It is well known from SPM, however, that reliable identiﬁcation of the variables primarily responsible for this
diﬀerence is hampered by the smearing eﬀect, which is a result of the PCA step. To avoid this problem, we
propose to combine estimation of the MD with variable selection via an l1-norm penalty instead of using
dimension reduction. This way a sparse MD metric is obtained.
The eﬀectiveness of this method is illustrated by several simulation studies and its application to urine 1H-
NMR metabolomics data for diagnosis of multiple inborn errors of metabolism.
1. Introduction
Metabolomics refers to the use of high-dimensional analytical
technologies for the global and unbiased measurement of metabolites
in a single biological sample such as urine or blood [1–3]. Through
measuring these small molecules, the metabolic phenotype (metabo-
type) of individuals is studied to inform on their health status. The
metabotype is dependent on the complex interplay between the genetic
proﬁle and environmental factors such as the gut microbial composi-
tion, lifestyle and diet, and varies greatly between individuals and
populations. Because of this metabolomics has (in concert with other
–omics techniques) an application in population-based health care as
well as precision medicine [2,3]. For example, metabolomics has been
used to diagnose cancer states, diabetes, cardiovascular diseases,
neurological diseases and inborn errors of metabolism (IEM) amongst
others [2,4–7].
Commonly, a metabolomics experiment involves hundreds to thou-
sands of measured variables per patient. Therefore, analysis of the
acquired data with (multivariate) statistical approaches is a crucial step
e.g. to diagnose a disease or monitor the healthy state [7,8]. Typically, a
case-control approach is used where two-class classiﬁcation techniques
such as LDA, (O)-PLS-DA, and SVM are used to model the metabolic
diﬀerences between the groups of samples [7,8]. Despite many suc-
cesses, this approach might be impractical in a clinical setting. It
assumes that both groups are well deﬁned biologically and that the
metabolic diﬀerences observed at the group (population) level carry
over to the level of the individual patient [9]. Often, however, this is not
the case due to individual exposures and response characteristics to e.g.
disease or treatment [10]. In other words, the case-control comparison
may not be a two-class problem at all. The individual responses are
hypothesized to overlap in two-class classiﬁcation models and may
therefore be very challenging to detect this way [11]. Moreover, in the
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case of diagnosis of rare diseases typically too few samples are available
for a useful two-class comparison between patients and controls; a
separate model is required for each disease; and unknown metabolic
perturbations, i.e. caused by an unexpected response to treatment may
not be detected or falsely interpreted. Clearly, statistical modeling
approaches beyond population-based case-control models are required.
Recently, Engel et al. transferred the class-modeling framework
used in e.g. statistical process monitoring (SPM) for monitoring of
industrial processes to the clinical ﬁeld as an alternative or comple-
mentary tool for comparing cases to controls in metabolomics [4]. They
coined the approach statistical health monitoring (SHM). It oﬀers an
intuitive way to assess the disease response in individual patients,
where disease is seen as an extreme of the normal range (normal
operating conditions; NOC) or as an abnormal deviation from normal
functioning within this range. Note that SHM is not limited to this
application and can be used for identiﬁcation of any abnormal
metabotype compared to the control samples (e.g. due to treatment).
We use disease diagnosis as a running example throughout this text. An
example is shown in Fig. 1. A set of control samples is used to
multivariately deﬁne the NOC represented by the black ellipse in the
ﬁgure. The NOC can be deﬁned for the population, or for the individual.
In this example, the patient sample falls outside the black ellipse and is
marked as signiﬁcantly diﬀerent. A second step is used to determine
which pattern of variables is primarily responsible for this diﬀerence
(the abnormal variables). This way, disease responses are assessed in an
individual manner. Engel et al. successfully used SHM for diagnosis of
orphan diseases [4]. The method was used by Del Carratore et al. for
biomarker discovery for hepatocellular carcinoma [9]. They showed
that by means of the individual predictions of SHM several metabolites
that were identiﬁed as a possible biomarker by a two-class classiﬁcation
approach were false positive identiﬁcations. Recently, Marquand et al.
proposed a similar approach (normative modeling) to study brain
functioning on the basis of functional magnetic resonance imaging
(fMRI) data [12].
The two-dimensional example above uses the Mahalanobis distance
(MD) to compare the patient to the NOC [4]. However, it is well known
that the MD cannot be estimated reliably for high-dimensional meta-
bolomics data where the number of control samples is (much) smaller
than the number of variables [13]. SHM circumvents these issues by
projecting the data to a lower dimensional space using principal
component analysis (PCA), similar to soft independent modeling
of class analogy (SIMCA) and several SPM approaches [4,14–18].
Hotelling's T2 statistic and the Q-statistic are used to determine whether
a given patient deviates from the NOC in the space spanned by the
selected principal components and its orthogonal complement, respec-
tively. Contribution plots based on the relative partial decomposition
criterion are used to identify the variables (metabolites) that mainly
contributed to this deviation. A major drawback of the PCA step is,
however, that it allows for interaction between the abnormal variables
(i.e. variables on which the patient diﬀers from NOC) and the normal
variables [19,20]. Because of this, reliable identiﬁcation of the abnor-
mal variables is challenging (normal variables appear to be abnormal).
This is sometimes referred to as the smearing eﬀect and hampers
disease diagnosis. Additionally, selection of the correct number of
principal components is a crucial step [21]. In our experience, standard
selection approaches such as screeplots do not provide a clear solution
for metabolomics data.
In this paper we propose an alternative SHM method, that is, sparse
SHM (sSHM). The key idea consists of combining the MD with variable
selection through an l1-norm constraint. This way a sparse MD metric is
obtained. Variable selection oﬀers multiple advantages. Firstly, subtle
diﬀerences between the patient and NOC can be detected this way
while they could be masked by the accumulative noise eﬀect of
irrelevant variables when no variable selection is applied (i.e. when
the MD is used). Secondly, dimension reduction by PCA is not required
anymore for analysis of high-dimensional data. This way the smearing
eﬀect is avoided. Because of this, sSHM identiﬁes abnormal variables
more reliably compared to SHM (which uses PCA) while having similar
power to detect patients that deviate from NOC as will be shown by
simulation. A fast algorithm is employed to compute the entire solution
path of the model, i.e. it ﬁnds all solutions with 1,2, ⋯,p selected
variables, where p corresponds to the total number of variables in the
data. This path can be graphically depicted and provides an intuitive
way to identify those variables on which the patient diﬀers most from
the NOC, i.e. the disease response of the patient.
The next section will outline the concepts of sSHM and its
mathematical background. We expect the method to also be applicable
to problems encountered in other ﬁelds such as industrial process
monitoring and food authentication. Therefore, this section also high-
lights the connections sSHM to some of the class-modeling approaches
that are used in these ﬁelds [14–18]. The subsequent sections detail the
simulation study that was carried out to compare the properties of SHM
to those of sSHM, and the application of sSHM to a case study involving
the diagnosis of orphan diseases based on the metabolic proﬁle of
individual patients.
2. Theory
In sSHM an individual patient sample is compared to the NOC in
two steps. In the ﬁrst step the patient data is matched against the NOC
and marked as normal (healthy) or possibly abnormal (possibly ill).
Note that a similar strategy is used in industrial process monitoring
(‘healthy’ data is obtained when the process is in-control) and food
authentication (‘healthy’ samples correspond to a certain product or
food type) [14,17]. When a sample is marked as abnormal a second step
is used to identify the abnormal variables, i.e. the disease response in
this individual.
Below, it is ﬁrst described how the Mahalanobis distance can be
used for analysis of low-dimensional data. Next, the sSHM model,
which combines the MD-statistic with variable selection, is introduced
for analysis of high-dimensional problems. Due to variable selection
more subtle diﬀerences between the patient and NOC can be detected in
the ﬁrst step. Additionally, the disease response can be better identiﬁed
in the second step. Finally, the SHM model and its associated issue of
variable smearing are brieﬂy reviewed.
2.1. The Mahalanobis distance
To be able to compare a patient to NOC, a set of healthy control
Fig. 1. Comparison of a patient (marked red) to a set of controls (marked blue) by the
Mahalanobis distance. Note that the solid black line corresponds to the 95% conﬁdence
sphere, i.e. the normal range. The dotted arrow indicates the direction of canonical
variate a, which is used to determine on which variables the patient diﬀered most from
the normal range. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article).
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samples (Xh) that represent the NOC well has to be selected. Note that
the choice of control samples deﬁnes what kind of patterns in the
patient sample will be marked as abnormal. For example, if the patient
data contains signal due to paracetamol intake, but the NOC data does
not, this signal will be marked as abnormal. More details regarding the
choice of NOC samples in the context of SHM are provided in [4]. We
assume that the distribution of the NOC samples is multivariate normal
(possibly after a suitable transformation of the data).
First, the patient is compared to the NOC by the squared
Mahalanobis distance (MD2) [22]:
MD cx μ Σ x μ= ( − ) ( − ) >p h p h
T2 −1
(1)
where xp, μh, and Σ indicate the row vector of patient data, the mean
vector of the control samples, and covariance matrix of the control
samples, respectively. Geometrically, expression 1 tests whether the
patient sample falls inside the conﬁdence sphere of the control samples,
where the upper limit c is traditionally derived from a scaled F-
distribution [22]. Note that the sphere deﬁnes the NOC: any sample
that falls inside the sphere is marked as normal. The location and shape
of the NOC sphere are deﬁned by μh and Σ. An example is shown in
Fig. 1. Note that Eq. (1) deﬁnes a (one-class) class model, which is also
known as unequal dispersed classes (UNEQ) [15,17].
If a sample falls outside the NOC it is abnormal and must be further
inspected. The MD can also be used for this step. For this purpose,
another interpretation of the MD is used. More speciﬁcally, it has been
shown that the squared Mahalanobis distance is the weighted distance
between the scalar projections of xp and μh onto the vector
a x μ Σ= [ − ]hp
−1, i.e. MD varx μ a X a= ([ − ] ) / ( )h h
2
p
T 2 T [23]. Vector a is a
canonical variate (CV) known from techniques such as Fisher LDA and
MANOVA. The CV is indicated by the dotted line in Fig. 1. It is a linear
combination of the variables that maximizes the diﬀerence between xp
and μh relative to the variance of the controls [23]. Therefore, the
coeﬃcients of a can be studied to determine on which variables the
patient sample diﬀered most from NOC, where large absolute coeﬃ-
cients indicate the abnormal variables. The abnormal variables are
interpreted as the individual disease response of the patient. A clinical
practitioner can use this information for example for disease diagnosis.
Typically, only a few of the measured variables are related to a
disease. However, all measured variables are taken into account by
MD2. As shown by Zimek et al., and also in Appendix A, the eﬀect
caused by the disease in a few variables may be masked by the normal
variation in the other variables [24]. This can result in a considerable
loss in power and hampers identiﬁcation of the abnormal variables
when inspecting direction a, especially when the eﬀect is small.
Additionally, Eq. (1) cannot be applied when the number of control
samples is smaller than the number of variables because the inverse of
Σ cannot be computed.
In this work a data-driven approach is introduced that automatically
takes only the most abnormal variables into account when comparing a
patient to the NOC. This increases the power of the MD2-test and
improves identiﬁcation of the abnormal variables. Additionally, the
method is applicable to high-dimensional data.
2.2. Sparse statistical health monitoring
Sparse SHM combines estimation of the MD with variable selection.
A ﬂowchart highlighting the main steps of the approach is shown in
Fig. 2.
The deﬁning feature of our approach is that we ﬁrst estimate the
canonical variate a (step 1a) before the MD is computed (step 1b).
Additionally, we regularize estimation of direction a with an ℓ1-norm
constraint. This constraint is well known from techniques such as the
LASSO and the elastic net [25]. It has the sparsity property in the sense
that it will force some coeﬃcients in a to be exactly zero indicating
variables on which the patient was similar to the NOC. A (sparse) MD is
calculated using sparse estimate(s) of a to determine if the patient
diﬀers signiﬁcantly from the NOC (step 2). Note that the ℓ1-norm
constraint eﬀectively introduces a variable selection step since only the
variables with a nonzero coeﬃcient in a contribute to the estimate of
the MD. Because of this sSHM can be directly applied to high-
dimensional data, and no dimension reduction using e.g. PCA is
required. Sparse estimation of a is also very useful to identify the
abnormal variables (step 3) since they are usually among the ﬁrst
variables that are selected.
2.2.1. Step 1a: sparse estimation of canonical vector a
To be able to combine estimation of canonical variate a with a
constraint, we ﬁrst note that a can be estimated by maximizing the
Rayleigh quotient aa d d a Σa[ ( ) ]/[ ]T T T , where d x μ= −p h. Wu et al.
showed that maximizing the Rayleigh coeﬃcient is equal to the
following expression [26]:
argmin a s ta Σa x μ aˆ = ( ) . . ( − ) = 1T p h
T
a (2)
Inspired by sparse linear discriminant analysis (LDA) [26], we
propose to include an ℓ1-norm constraint in expression 2 to obtain a
sparse solution of the direction a, i.e. incorporate variable selection
(step 1a):





where ai indicates the i-th coeﬃcient of a, and λ is a ﬁxed constant. The
value of λ controls the amount of variables that are included in the
model; when λ is small, most of the ai will be exactly zero. Expression 3
can be solved in diﬀerent ways. Here a fast algorithm was used as
developed by Wu et al. to solve a sparse LDA problem [26,27]. To
stabilize the algorithm and allow for selection of more than n variables
when n< p, p n2*log ( )/ was added to the diagonal of Σ [26]. Here, p and
n are the number of variables and training samples in matrix Xh
respectively. This step will be referred to as regularization of Σ.
2.2.2. Steps 1b and 2: comparison of a patient to the NOC
In sSHM, the dissimilarity between the patient and the NOC is
evaluated by the squared MD using a sparse estimate of a (step 1b):







where MDi2 indicates a sparse squared Mahalanobis distance based on i
selected variables. As mentioned above, the power of the method is
increased by variable selection. The variables are selected in a data-
driven fashion by Eq. (3), where aλi is its solution with λ λ= i chosen such
that i variables are selected. Typically, a range of constants
λ λ λ< <⋯<i i ik1 2 exists such that Eq. (3) gives a solution with i nonzero
coeﬃcients (i selected variables). The value for λi in (4) is always set to
the highest constant in this sequence, i.e. λ λ=i ik .
For each patient there is an optimal number of selected variables
such that a possible diﬀerence with the NOC can be best observed (step
2). This number depends on how much the patient diﬀers from the NOC
in the abnormal variables with respect to the accumulating noise due to
normal variation in the other variables (see Appendix A). In practice,
however, this number is unknown. In this work we use two approaches
to resolve this issue (see box parameter optimization in Fig. 2). The ﬁrst
option is a practical approach that was suggested by Wang et al. in the
context of industrial process monitoring where they used domain
knowledge to restrict the solution of their sparse model to i variables
[28]. In other words, Eq. (4) is used for i selected variables. In the
context of sSHM this means that the clinical practitioner must have a
rough idea regarding how many variables are aﬀected by e.g. a disease
in the patient data. Our simulation studies show that often a signiﬁcant
diﬀerence from NOC can be detected by selecting roughly this expected
number of variables. The second option is to determine i from the data
by selecting that number of variables for which the largest distance
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MDi2 is observed. However, this is not a straightforward task since
distances based on diﬀerent amounts of selected variables are not
directly comparable [24]. Therefore, a normalization step is used to
fairly compare the MDi2-values:
MD MD E MD
Var MD
= max − ( )








where E MD( )i2 and Var MD( )i2 are the mean and variance of MDi2 for
control samples, respectively. The values for E MD( )i2 and Var MD( )i2 are
estimated from the control data by means of leave-one-out cross-
validation (LOO-CV). Zou et al. and Capizzi et al. also used this
approach to select the optimal number of variables in their sparse
industrial process control methods [29,30].
After selecting a speciﬁc number of variables a signiﬁcance test is
required to determine if the patient indeed diﬀers from NOC. For this
purpose, the upper limit of MDi2 and MDmax2 is estimated from a
generalized extreme value distribution. Note that the signiﬁcance test
does not test whether the sample is signiﬁcantly diﬀerent from the NOC
on the speciﬁc variables selected by Eq. (3) for that sample. The fact
that each sample (control and patient) may diﬀer most from NOC on
completely diﬀerent variables is taken into account. More details are
provided in Appendix B.
2.2.3. Step 3: identiﬁcation of abnormal variables
As described above, the ﬁrst steps of sSHM are to use Eqs. (3)–(5) to
detect a signiﬁcant diﬀerence between the patient and the controls. The
third step involves interpretation: the goal is to identify most (all)
abnormal variables, e.g. the individual disease response. Again, vari-
able selection is useful in this respect. In principle, the abnormal
variables should be selected ﬁrst by the model and can thereby be
identiﬁed this way. However, it is unclear how many abnormal
variables are present in a sample and should therefore be selected.
Expression 5 seems to be useful to automatically select all relevant
variables. However, our simulations show that this test (that is designed
to best detect a diﬀerence between a patient and NOC) does not always
reliably identify all of the abnormal variables (see e.g. Fig. 7). Similarly,
when the coeﬃcients of aλi for a speciﬁc number of selected variables
are inspected it can be that too many noise variables are included
masking the relevant variables (see e.g. Fig. 4a), or that not all relevant
variables are selected. Therefore, we propose to inspect multiple
solutions with diﬀerent numbers of selected variables together in the
so-called solution path ﬁgure to identify most abnormal variables.
Examples will be provided in the results section in Figs. 5 and 7 and in
Appendix F.
The solution path oﬀers an intuitive way to see in which order the
variables were selected by sSHM. Based on this information the
variables can be ranked, where it is assumed that the most abnormal
variables are selected ﬁrst (step 3 in Fig. 2). A clinical practitioner can
inspect the top ranked variables to determine the patient's response to
e.g. a disease, where the number of variables to inspect can be chosen
based on practical considerations (i.e. it is not feasible to inspect more
than 50 variables). Additionally, as soon as it is clear that a number of
variables corresponding to a speciﬁc diagnostic marker have been
Fig. 2. Flowchart highlighting the main steps in sSHM.
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selected, the solution path oﬀers an intuitive way to quickly assess the
selection rank of other variables that are biologically related to this
marker.
2.3. Statistical health monitoring
As mentioned above, SHM can also be used to compare a patient
sample to the NOC. Below, we brieﬂy review the main steps in SHM.
For more details we refer the reader to [4].
SHM combines the MD (Eq. (1)) with dimension reduction instead
of variable selection (as in sSHM, see Section 2.2) [4]. More speciﬁcally,
PCA is used to reduce the dimension of the data and compare a patient
sample to the NOC in two diﬀerent subspaces:
MD x μ Σ x μ
x μ PΛ P x μ
x μ PΛ P x μ T T
= ( − ) ( − )
= ( − ) ( − )
+( − ) ( − ) = +















where the columns in P and the diagonal elements in matrix Λ indicate
the k eigenvectors (PC) and eigenvalues of Σ that are retained in the
model, respectively. The matrices P∼ and Λ∼ indicate the p k− residual
eigenvectors and eigenvalues. The statistic T 2 is used to monitor the
principal component subspace spanned by the k PCs. The residual space
is typically monitored by the Q-statistic since TRS2 cannot be applied
when the control data has more variables than sample [4]:
Q e= p 2 (7)
where e x μ x μ PP x μ I PP= ( − ) − ( − ) = ( − )( − )p p h p h
T
p h
T is the residual
information in the patient data that is not captured by the ﬁrst k
principal components, and I indicates the identity matrix.
Identiﬁcation of abnormal variables in SHM (for outlying samples as
judged by the T 2 and/or Q-statistic) is based on inspection of contribu-
tion plots. These highlight the contribution of each variable to the T 2 or
Q-statistic [4,14,19]. For example, contributions to the Q-statistic can




⎠⎟q e ζ x μ x μ PP ζ= = ([( − ) − ( − ) ] )i p i
T








T is the ith column of matrix I and qi indicates the contribution
of variable i to the Q-statistic [4,19]. Variables with the highest
contribution values are ﬂagged as most abnormal. From Eq. (8) it can
be seen that contributions to the Q-statistic are computed by projection
of the data onto a lower dimensional space spanned by the selected
principal components ( x μ P( − )p h ) (data compression) and subsequent
expansion to the original measurement space ( x μ PP( − )p h
T ) [20]. This
allows for the ‘interaction’ between the abnormal variables and the
normal variables [19,20,31]. Because of this, reliable identiﬁcation of
the abnormal variables is challenging (e.g. normal variables can have
high contributions and appear to be abnormal while abnormal variables
can be obscured). This is sometimes referred to as the variable smearing
eﬀect [19,20,31]. Note that variable smearing also occurs for the
T 2-statistic and other contribution criteria (e.g. partial decomposition),
and is also expected to occur when dimension reduction is carried out
using other PCA-based approaches (e.g. sparse PCA) [19,20].
Variable smearing greatly hampers reliable identiﬁcation of abnor-
mal variables, as will be shown in Section 4.2 and was also shown
numerous times in the industrial process monitoring literature
[19,20,31]. This is a major drawback of the SHM approach. The
variable smearing eﬀect was the main motivation of the work devel-
oped in Section 2.2. It is avoided in sSHM since no dimension reduction
by PCA is used.
3. Method
We use simulated and real data to investigate the properties of the
sSHM model under diﬀerent structures of the NOC. The simulation
study was also used to compare sSHM to competitive methods such as
SHM. All methods were applied according to the protocols described in
the original papers [4,14,30]. In the main text of this paper, we focus on
the comparison between sSHM and SHM with respect to identiﬁcation
of the abnormal variables in a patient (step 3). We refer the reader to
appendices D and E for a comparison of the classiﬁcation accuracy (as
NOC or non-NOC), sensitivity and speciﬁcity of the approaches (step 2).
3.1. Simulation design
Throughout the simulation it was assumed that the distribution of
healthy controls was multivariate normal N 0 Σ( , ). The covariance
matrix Σ was constructed by multiplication of a predeﬁned correlation
structure R with variance values drawn from the uniform distribution
U(0.1,16).
It is diﬃcult to simulate correlation structures R that closely
resemble the complex structures of metabolomics data. Therefore, we
studied three “simple” structures to be able to systematically explore
the properties of the sSHM method. Note that the simulated data
contained some aspects of real metabolomics data such as correlations
between variables, grouping of variables (in e.g. metabolic pathways),
and irrelevant noise variables. Additionally, we applied sSHM to real
NMR metabolomics data to study its performance for more complicated
correlations (see Section 3.2 below). The following correlation struc-
tures were considered in the simulation study:
1. R1 Common correlation: all variables were correlated to each other
with value ρ
2. R2 Block-diagonal: blocks of variables were correlated to each other
with value ρ. The diﬀerent blocks were uncorrelated. Each block
contained 10 variables. The ﬁrst 10 variables corresponded to the
ﬁrst block, variables 11 to 20 to the second block, etc.
3. R3 Toeplitz structure: variables close to each other were more
highly correlated compared to variables that were far apart. The
distance between variables with indices p1 and p2 was deﬁned as
p p1− 2 . For example, the distance between the ﬁrst and fourth
variable in the data is equal to three. The correlation between
variables was given by ρ p p1− 2 .
The correlation ρ was set to 0, 0.4, 0.6, and 0.8. The correlation
structures are visualized in Fig. 3.
In the simulation the number of variables in the data set was varied
between 10 and 100. Additionally, the number of control samples that
was used to train the sSHM model (i.e. used to estimate μhand Σ in Eq.
(3)) was 50 or 1000. These samples were drawn from N 0 Σ( , ) with a
speciﬁc covariance matrix as deﬁned above. Next, test samples were
simulated. These samples were diﬀerent from NOC on two variables.
Correct identiﬁcation by SHM is not guaranteed in this case due to
variable smearing [14]. Therefore, this simulation design was enough
to highlight the main diﬀerence between SHM and sSHM for identiﬁca-
tion of the disease response in individual patients. The amount of
diﬀerence was varied by constant f , which ranged from 0 to 3 in steps
of 0.25. We will refer to this constant as the fault magnitude. Note that
the test samples were similar to the controls when the fault magnitude
was 0. In this case sSHM should not mark them as signiﬁcantly diﬀerent
from NOC. A thousand samples were simulated for each value of f as
follows to ensure that the canonical vector a was (approximately)
sparse (had two non-zero coeﬃcients):
fx x ζ ζ Σ= + ( + )p h i j (9)
where xh indicates a row vector that was drawn from N 0 Σ( , ), i.e. a
control sample. Note that half of the samples had a negative sign in f .
The two abnormal variables were deﬁned by unit vectors ζi and ζj,
where i and j indicated their indices. For each simulated sample, the
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indices i and j were drawn from a uniform distribution. Prior to
construction of the models, all simulated samples were autoscaled to
the mean and standard deviation of their corresponding control samples.
3.2. Diagnosis of inborn errors of metabolism
To assess the value of sSHM for disease diagnosis, a set of urine
samples of 193 healthy children and a set of 24 patients with an IEM
was measured using proton NMR spectroscopy [4]. Eighteen patients
were known to suﬀer from one of seven diﬀerent IEM. For the other six
patients, no IEM was diagnosed, but signals related to commonly
prescribed drugs such as depakine and paracetamol were found in the
NMR spectra by visual inspection of the data by a clinical expert. A
subject had to be between 4 and 12 years old to participate in the study
and be of Dutch ancestry. An equal amount of males and females were
selected. No other selection criteria such as lifestyle or diet were
imposed. The study was approved by the medical ethical committee of
the Radboud University Medical Centre in Nijmegen, The Netherlands.
More details regarding the data, including information regarding the
measurement and subsequent processing of the NMR spectra, can be
found in [4]. Brieﬂy, the regions 0.2–4.7 ppm and 5.0–10.0 ppm were
selected for further analysis. Next, the urine NMR spectra were
normalized to the creatinine concentration to correct for dilution
eﬀects. Equidistant binning with a bin size of 0.04 ppm was used to
reduce the normalized data from 30,888 measurements to 246 bins.
Finally, Pareto scaling data was applied to the data for reasons justiﬁed
in Section 4.3.
Since outliers in the set of controls can heavily inﬂuence an sSHM
model, the spectra of the 193 healthy children were inspected using
robust PCA [32]. Seventeen samples with abnormal patterns related to
dietary inﬂuences and drug intake were identiﬁed. These samples were
marked as abnormal and used to validate the sSHM model since
detection of abnormal patterns due to diet and drugs is in principle
no diﬀerent from the detection of abnormalities related to disease. The
set of 24 patients was also used for this purpose. Additionally, another
set of 56 samples from the remaining 176 healthy controls was used to
validate the model. The remaining healthy control samples were used to
deﬁne the NOC and train the sSHM model. Based on their value in Eq.
(5), it was observed during cross-validation of the 120 training samples
that 2 of these samples greatly diﬀered from the others. Visual
inspection of the data showed that this was due to bad baseline
correction and water suppression. Therefore, these samples were
excluded from further analysis.
To clearly demonstrate the advantage of variable selection by sSHM
the analysis was repeated 15 times where each time the data was
concatenated with a block of 100 additional random variables (noise
bins). The bins were normally distributed with zero mean and a
standard deviation chosen such that the intensity of the noise bins
was roughly equal to the median peak intensity of the control samples.
4. Results
4.1. Individual analysis of the simulated samples
As mentioned in Section 3.1, the main properties of the sSHM model
were studied by simulation. A large number of control and patient
samples were simulated for diﬀerent structures of the NOC. Below, the
analysis of a single simulated sample is described to demonstrate how
the method can be used on a case-by-case basis. Next, sSHM is
compared to SHM where we focus on identiﬁcation of abnormal
variables (step 3) since the main diﬀerences between the methods
become visible in this step. Additional details of the simulation study
Fig. 3. A graphical representation of (a) the common variance, (b) the block diagonal, and (c) the Toeplitz, correlation structures with ρ = 0.6 that were used in the simulation study.
Structures (a–c) are equal to an independent structure when the correlation is zero ρ = 0. This is shown in panel d.
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such as the empirical type I (1-sensitivity) and type II (1-speciﬁcity)
error rates of the sSHM model (for the detection of normal and
abnormal samples, respectively) are presented in Appendix C. We refer
the reader to Appendix E for a comparison of the sensitivity and
speciﬁcity of SHM and sSHM.
4.1.1. Steps 1 and 2: detection of abnormal samples
Here, we consider a single simulated sample (f =2) for the case
where the correlation matrix of the control samples had a block
diagonal structure with ρ = 0.4 and 50 training samples were available.
The simulated sample was automatically compared to the NOC by
sSHM (step 2). As shown in Table 1, a signiﬁcant diﬀerence could be
observed due to variable selection. When using a signiﬁcance level of
5%, for example, no signiﬁcant diﬀerence was observed when all
variables were taken into account (i.e. when the normal MD was used):
the eﬀect of the abnormal variables was masked by the “noise” of the
other variables. In contrast a clear signiﬁcant diﬀerence was observed
when only 2 variables were selected. The diﬀerence became less clearly
visible with additional selected variables. This was expected since the
simulated sample contained only two abnormal variables. In real
applications the number of variables that should be selected is
unknown. As shown in the table, the simple standardization suggested
in Eq. (5) (marked as automatic in the table) ignored enough irrelevant
variables such that a diﬀerence between the patient and the NOC was
observed: the observed p-value was similar as the p-value found for the
solution with 2 selected variables. Similar results were obtained for the
other simulations (see appendix C).
4.1.2. Step 3: identiﬁcation of abnormal variables
The observed signiﬁcant diﬀerence between the simulated sample
and the NOC suggested that the sample should be further investigated
to identify which variables were abnormal. Fig. 4a shows the estimates
of the coeﬃcients of the canonical vector a that were obtained when all
variables were selected. The abnormal variables (solid red circle, solid
red line) could barely be distinguished from the irrelevant variables
(blue empty circle, blue dotted line). Identiﬁcation was greatly
improved by the variable selection step in sSHM as shown in Fig. 4b.
In this case the abnormal variables were easily identiﬁed since they
were the only two variables that were selected.
In this simulation it was known that only 2 variables were
abnormal. In real applications, however, this number is not exactly
known and it can be diﬃcult to select the right solution to inspect.
Therefore, it is preferred to inspect multiple solutions together in the so-
called solution path ﬁgure (step 3). The path found for this simulation is
shown in Fig. 5. The solution path displays the estimated coeﬃcients of
a for all possible values of the ℓ1-norm constraint (see Eq. (3)). The lines
in the ﬁgure are the paths of the coeﬃcients shrinking towards zero as a
function of the penalty. This allows a clinical practitioner to see how
speciﬁc variables behaved as a function of the constraint. Note that the
x-axis has been scaled to have a maximum value of one.1 A value close
to 0 means that the l1-norm constraint was large and only a few
variables were selected (had nonzero coeﬃcient), while a value of 1
indicates that all variables were selected. The solutions corresponding
to Fig. 4a and 4b can be found at 0.22 and 1, respectively. Moving from
left to right in the solution path ﬁgure provides an intuitive way to see
at which points a variable had a nonzero coeﬃcient, i.e. was selected.
In this case, the solution path clearly shows that the abnormal variables
(red solid lines) were the ﬁrst two variables that were selected. This
demonstrates that the information in the solution path can be used to
rank the variables, where it is assumed that the abnormal variables are
among the ﬁrst selected ones.
Note that the solution found by automatic variable selection with
expression 5 selected only one of the two relevant variables. Therefore,
inspection of the solution path is preferred for identiﬁcation of
abnormal variables.
4.2. Comparison between SHM and sSHM
The main motivation for the development of sSHM was the
unreliable identiﬁcation of abnormal variables by SHM. Below, the
SHM and sSHM model are compared with respect to analysis of the
simulated data. The analysis of the data by SHM was carried out as
described in Section 2.3 and in [4]. It was observed that SHM and sSHM
had similar type I (1 – sensitivity) and type II (1 – speciﬁcity) error rates
with respect to identiﬁcation of signiﬁcant diﬀerences between the
simulated samples and the NOC (step 2). More details are provided in
Appendix E.
As expected, sSHM greatly outperformed SHM with respect to
identiﬁcation of the abnormal variables in the samples (step 3). This
is shown in Fig. 6 for the case that 50 training samples were available to
deﬁne the NOC and 100 variables. To allow for a fair comparison
between the diﬀerent approaches it was assumed that all samples were
correctly marked as signiﬁcantly diﬀerent from NOC. The x-axis in the
ﬁgure expresses the diﬀerence between the NOC and the simulated
patient as deﬁned by the fault magnitude ( f ) in Eq. (9). The y-axis
shows the percentage of simulated samples in which the abnormal
variables were correctly identiﬁed. Correct identiﬁcation was achieved
by sSHM when the ﬁrst two selected variables were the abnormal ones.
Identiﬁcation of abnormal variables in SHM was achieved by studying
the relative contribution values (of the Hotelling T2 and Q-statistics)
[4]. Correct identiﬁcation was achieved when the two abnormal
variables had the highest contribution values.
From Fig. 6 it is clear that for sSHM and SHM the identiﬁcation rate
improved when the diﬀerence between the patient and the NOC was
larger. However, as shown in Fig. 6 the identiﬁcation rate of SHM
remained below 40% for the values of f considered. This poor
identiﬁcation rate is attributed to the smearing eﬀect (see Section
2.3). As mentioned earlier, sSHM does not use dimension reduction
with PCA and does therefore not suﬀer from the smearing eﬀect (see
Section 2.3). Therefore, considerable higher identiﬁcation rates were
achieved with sSHM. This was also observed for other variable and
sample sizes (see Appendix E).
4.3. Diagnosis of inborn errors of metabolism
Inborn errors of metabolism are a group of rare genetic defects that
collectively occur in roughly 1 out of every 2500 individuals [33].
Therefore, they are an important group of diseases to consider.
Unfortunately, standard classiﬁcation models such as Partial Least
Squares – Discriminant Analysis cannot be used to diagnose these
diseases since the number of training samples is extremely limited.
Recently, SHM was successfully used to analyze NMR data and diagnose
several IEM [4]. Below, we will use the same data to show the value of
sSHM in a practical example. As shown in Table 2, the data did not only
contain abnormal patient samples related to IEM, but also abnormal-
ities related to diet and medication. These abnormalities had already
Table 1
Accuracy of diﬀerent sSHM tests for health monitoring of a simulated patient sample.







1 The x-axis corresponds to the proportion of shrinkage (a a/λi λp) instead of the size of
the l1-norm constraint.
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been observed by visual inspection of the data by a clinical expert and
were also used to validate the sSHM approach since detection of
abnormal patterns due to diet and medication is in principle no
diﬀerent from detection of metabolites related to a disease.
First, the data were analyzed after autoscaling. An improvement of
roughly 10% in terms of the percentage of correctly identiﬁed patient
samples (speciﬁcity) was observed due to variable selection by sSHM.
However, subsequent correct identiﬁcation of the abnormal metabolites
was hampered by the large inﬂuence of baseline signal on the model
due to the autoscaling. Therefore, it was decided to apply Pareto scaling
to the data instead. Additionally, the regularization constant (see
Section 2.2.1) was increased to p n4*log ( )/ . Sensitivity and speciﬁcity
of the model were not aﬀected by this stronger regularization. How-
ever, based on inspection of the solution path of a single sample, fewer
baseline bins were amongst the ﬁrst variables selected (see Section 5 for
more details).
As shown in Table 3, the eﬀect of variable selection on the number
of patient samples that were correctly ﬂagged as such (speciﬁcity) was
Fig. 4. The canonical vectors of an sSHM model where (a) all variables were selected and (b) 2 variables were selected. These results were obtained for analysis of the same simulated
patient sample as analysed in Table 1. It was known that two variables were abnormal. These are marked red in the ﬁgure. The irrelevant (normal) variables are marked blue. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
Fig. 5. Solution path of an sSHM model applied to a simulated patient sample. The known
abnormal variables are indicated by the solid red lines. The irrelevant (normal) variables
are marked by dotted blue lines. The vertical dotted line indicates the solution found by
automatic variable selection (Eq. (5)). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article).
Fig. 6. Correct identiﬁcation of the abnormal variables in simulated patient samples by
sSHM, and SHM as a function of the size of the abnormality.
Table 2
An overview of the abnormal samples that were investigated by NMR metabolomics in combination with sSHM. Note that the data was also analyzed in [4]. More details regarding the
abnormalities can be found in this reference. The diagnostic metabolites that were used to diagnose each IEM are included in Appendix F.
Disease (IEM) n Dietary n Medication n Other n
3β-Hydroxy-Δ-C -27 steroid dehydrogenase deﬁciency 1 Cyclamate (artiﬁcial sweetener) 3 Depakinea 2 Bacterial contamination 3
3-Methylcrotonyl CoA carboxylase deﬁciency 1 Fish 5 Paracetamol 5 High Taurine signal (cause unknown) 3





a Intake of piracetam or sabril medication was also detected in these samples.
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less clear for the Pareto-scaled data. sSHM in combination with a large
number of selected variables could also be used to identify the
abnormal samples. This is attributed to the reduced inﬂuence on the
model of noise signal close to the baseline of the NMR spectrum. To
clearly show the advantage of the variable selection step for the Pareto
scaled data, the analysis was repeated 15 times. In each repetition the
data was concatenated with a block of 100 irrelevant variables. As
shown in Table 3, the percentage of correctly classiﬁed samples was
clearly improved by variable selection in this case. Note that the highest
accuracy and speciﬁcity were obtained when 2 variables were selected,
although the automatic selection by Eq. (5) was very competitive. All
abnormal samples due to an IEM were correctly identiﬁed by sSHM.
Four other samples were not correctly identiﬁed. The abnormality in
these samples was related to cyclamate (2x), paracetamol, and bacterial
contamination.
After a sample had been marked as abnormal, the next step (step 3)
was to identify the abnormal metabolites. Again, it was observed that
expression 5 could not be used in this step as indicated in e.g. Fig. 7a.
Via inspection of the solution path ﬁgures, however, all IEM were
successfully diagnosed and all dietary and medication abnormalities
were successfully identiﬁed. Two examples are presented in Fig. 7. The
solution paths of the other samples are shown in Appendix F. In these
ﬁgures the solid red lines indicate the variables (resonances in the NMR
spectrum) that were known to be related to the IEM and other
abnormalities in the data. For clarity the relevant features are indicated
in the NMR spectrum in panels b and d. In each case the variable
selection rank (VS) indicates when the variable was selected by the
sSHM model, where “1” corresponds to the ﬁrst variable that was
selected (the ﬁrst nonzero coeﬃcient in the left of panel a), etc. The
IEM and other abnormalities were correctly diagnosed when enough of
the relevant (red) variables had low VS values.
In the solution path of the ﬁrst example in Fig. 7a the ﬁrst four bins
that were selected (VS 1 – 4) corresponded to resonances around 6.76
ppm and 3.64 ppm. This indicated that the metabolic proﬁle of this
patient contained abnormal amounts of homogentisic acid. Thanks to
this, the patient was diagnosed with the IEM alkaptonuria, an inborn
error of metabolism aﬀecting tyrosine catabolism. In this example all
known resonances (red lines) were selected ﬁrst by the model and the
diagnosis was clearly made. The second example is shown in Fig. 7c.
This example is considered more diﬃcult since it involved many
Table 3
Accuracy of diﬀerent sSHM tests for health monitoring of 56 healthy and 41 abnormal
samples. The original data as well as a concatenation of the data with 100 irrelevant bins
was analysed. The sensitivity and speciﬁcity indicate the percentage of correctly classiﬁed
healthy and abnormal samples, respectively. Note that high numbers of variables could be
selected due to the regularization of the sample covariance matrix Σ that was applied (see
Section 2.2.1). The reported results for the analysis with 100 irrelevant bins correspond to
the average of 15 repetitions.
Number of
irrelevant bins
Number of selected bins Accuracy Sensitivity Speciﬁcity
0 Manual 2 95.1 100 90.2
20 95.1 100 90.2
50 95.1 100 90.2
100 93.9 100 87.8
200 93.9 100 87.8
Automatic 1−246 95.1 100 90.2
100 Manual 2 95.1 100 90.2
20 93.7 99.6 87.8
50 92.8 98.8 86.8
100 92.7 99.6 85.7
200 92.3 99.9 84.7
Automatic 1−346 94.3 99.8 88.8
Fig. 7. (a, c) Variable selection paths of sSHM models applied to the NMR data of a urine sample of two patients. The relevant diagnostic resonances are indicated by the solid red lines.
The vertical dotted line indicates the solution of the maximum test (Eq. (5). (b, d) Plot of the NMR spectra highlighting the relevant diagnostic resonances and their variable selection rank
(VS). The metabolites are markers for (a, b) Alkaptonuria disease, and (c, d) intake of paracetamol by the patient.
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resonances in many diﬀerent parts of the NMR spectrum. The bins
centred around 2.16, 5.14, 7.13, 7.31, 7.45, 9.67 and 9.78 ppm were
clearly marked by the model as abnormal. All these features had VS
values lower than 20. This suggested that the metabolites acetamino-
phen, acetaminophen-glucuronide, and acetaminophen-sulphate were
present in high concentrations. This was caused by intake of para-
cetamol by this individual.
5. Discussion
In this work, sSHM was introduced for (1) assessment of the
deviation from the normal range and (2) identiﬁcation of the variables
related to this diﬀerence in individual patients. The properties of the
method were investigated by simulation and compared to those of
SHM. Additionally, sSHM was successfully applied to real NMR
metabolomics for diagnosis of several IEM. The same data was
previously investigated by the SHM model in chapter 5 [4]. Therefore,
sSHM and SHM can be compared with respect to this application.
The methods had similar power to identify normal and abnormal
samples. Compared to sSHM, the speciﬁcity (correct identiﬁcation of
patient samples) of SHM was slightly higher for this dataset. The
speciﬁcity of SHM, however, dropped considerably after the addition of
additional noise variables while that of sSHM remained very robust as
shown in Table 3. Additionally, interpretation of the SHM contribution
plots for identiﬁcation of abnormal variables was not straightforward
because of two reasons: (1) the contribution values couldn’t be reliably
interpreted due to the so-called smearing eﬀect (see Section 2.3 and
Appendix E), and (2) the contributions of the relevant variables diﬀered
by orders of magnitude making it diﬃcult to visually inspect the results.
It must be remarked, though, that for this data set inspection of the
highest contributions identiﬁed enough key variables as abnormal to
make a correct diagnosis. In contrast, the sSHM solution path oﬀered an
easy tool to identify the abnormal variables as shown in Fig. 7. The
method does not suﬀer from the smearing eﬀect allowing for much
more reliable identiﬁcation of these variables. This was conﬁrmed by
repeating the simulation study described in Section 4.3 with the
correlation structure of the 1H-NMR data. This clearly shows that sSHM
is a useful alternative to SHM in a clinical setting.
The idea of combining the Mahalanobis distance with variable
selection is not new. Several other methods have been proposed in the
context of industrial process monitoring [28–30]. These methods apply
variable selection directly to the diﬀerence between the patient and the
centre of the controls, i.e. x μ−p h. However, this does not guarantee
that the canonical variate a x μ Σ= [ − ]hp
−1 is sparse. The CV is directly
penalized by sSHM. Preliminary simulation studies shown in Appendix
E suggest that sSHM is therefore better able to identify abnormal
variables in many situations. Similar results have been found for the
closely related problem of sparse LDA [34].
It has been shown for sparse linear regression that addition of an
additional l2-norm (ridge-type) penalty can improve prediction and
identiﬁcation of important variables in cases of highly collinear and / or
ultra-high dimensional data [25]. Such a penalty results in sSHM in Σ in
expression 3 being replaced by δΣ Σ I= +reg , with tuning parameter δ
[26]. This form of regularization decorrelates the data; matrix Σreg
approaches a diagonal matrix for large δ and the sSHM procedure will
essentially select the largest absolute values of x μ( − )p h . The algorithm
used to solve expression 3 uses δ p n= 2*log ( )/ as suggested by Wu et al.
in the context of sparse LDA [26]. This was justiﬁed by the empirical
observation that l2-norm regularization seemed to stabilize the algo-
rithm, while the power was fairly robust to the choice of δ [26]. This
was also observed for sSHM in the simulation study in Section 4.2. For
analysis of real NMR metabolomics data, however, variable selection
was improved by increasing δ to p n4*log ( )/ (see Section 4.3). Addi-
tionally, we note that δ p n= 2*log ( )/ is suggested for autoscaled data
(where the diagonal elements of Σ all equal 1), but might be suboptimal
for diﬀerently processed data (with much larger diagonal elements of Σ,
for example). This suggests that the choice of tuning parameter δ (next
to the number of variables to select) oﬀers an interesting direction for
further improvement of sSHM. However, it is not immediately clear
how such tuning should be achieved, since the optimal values of δ for
detection of patients that are outside of NOC and selection of a limited
set of important abnormal variables in these patients do not need to be
the same. As mentioned in Section 4.3, the solution path might oﬀer
some insight regarding sensible values for δ since variables that clearly
correspond to baseline signal in e.g. an NMR spectrum should not be
among the ﬁrst selected variables. An interesting direction for future
research is oﬀered by stability selection [35]. Essentially, this method
aggregates the results of multiple variable selections applied to
subsamples of the data. For sparse linear regression (the LASSO) it
has been shown that variable selection may be markedly improved in
this way [35]. In a preliminary investigation we randomly selected
values for δ from a range of pre-deﬁned values, each time ﬁtting an
sSHM model to a subsample of the data presented in Section 4.3. Most
of the variables known to be abnormal were consistently among the
ﬁrst selected variables, while the baseline signal had a lower rank.
In this study it was shown that sSHM ranks the variables from
abnormal to normal by variable selection. A clinical practitioner can
use this information, which is visualized in the solution path ﬁgure, to
diagnose a disease. Currently, however, no clear guidelines exist on
how many of the top-ranked variables should be inspected. Eq. (5)
could clearly not be used for this purpose, nor is this expression based
on ﬁrm statistical theory. It would be interesting to develop another
strategy to obtain an upper bound. Stability selection also oﬀers an
interesting direction for future research in this respect since it allows for
error control on the expected number of falsely selected variables [35].
Another interesting direction for future research is to employ an initial
variable screening method to narrow the number of variables before
application of sSHM to a sample [36]. This could extend the applic-
ability of the method to larger data sets such as LC-MS data.
6. Conclusion
In this work an l1-norm penalized Mahalanobis distance was
proposed for identiﬁcation of disease biomarkers in individual patients.
Here, a disease is seen as an extreme from the normal range. We
demonstrated improved identiﬁcation of abnormal variables compared
to the use of PCA-based contribution plots (well known from statistical
process monitoring), which suﬀer from the smearing eﬀect. It was
shown how the method can be used for analysis of metabolomics data
for rapid screening of individual patients for a multitude of (rare)
diseases.
The method also oﬀers perspectives in the framework of precision
medicine and in non-life science applications such as industrial process
monitoring and food authentication.
The source code of the method will be made available at the
following github repository: https://github.com/JasperE/sSHM.
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